Håkansson and colleagues investigated the relationship between serum and CSF NfL levels, and brain atrophy in RRMS and CIS patients, and the subsequent disease progression (Håkansson et al., 2018[43]). This evidence concerns the gene NEFL and in situ carcinoma.